Citadel Advisors
IMNM icon

Citadel Advisors’s Immunome IMNM Stock Holding History

Citadel Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.57M Sell
71,900
-19,900
-22% -$443K ﹤0.01% 6611
2025
Q4 		$1.97M Buy
91,800
+37,500
+69% +$658K ﹤0.01% 5945
2025
Q3 		$636K Buy
54,300
+32,700
+151% +$325K ﹤0.01% 8549
2025
Q2 		$201K Buy
21,600
+6,000
+38% +$49.2K ﹤0.01% 10670
2025
Q1 		$105K Sell
15,600
-5,500
-26% -$52.8K ﹤0.01% 11382
2024
Q4 		$224K Sell
21,100
-17,000
-45% -$205K ﹤0.01% 10238
2024
Q3 		$557K Buy
38,100
+10,000
+36% +$142K ﹤0.01% 8035
2024
Q2 		$340K Buy
28,100
+6,700
+31% +$105K ﹤0.01% 8890
2024
Q1 		$528K Buy
21,400
+11,700
+121% +$237K ﹤0.01% 8277
2023
Q4 		$104K Buy
9,700
+4,000
+70% +$33.3K ﹤0.01% 10888
2023
Q3 		$47.6K Sell
5,700
-11,300
-66% -$83K ﹤0.01% 11816
2023
Q2 		$134K Buy
17,000
+8,100
+91% +$44.3K ﹤0.01% 10495
2023
Q1 		$44.4K Buy
+8,900
New +$43.5K ﹤0.01% 12314
2022
Q4 		– Sell
-26,500
Closed -$118K – 15151
2022
Q3 		$118K Sell
26,500
-15,600
-37% -$73.1K ﹤0.01% 10953
2022
Q2 		$135K Buy
42,100
+6,600
+19% +$24K ﹤0.01% 11090
2022
Q1 		$202K Sell
35,500
-13,100
-27% -$97.9K ﹤0.01% 11513
2021
Q4 		$630K Buy
48,600
+10,400
+27% +$185K ﹤0.01% 9099
2021
Q3 		$930K Buy
+38,200
New +$666K ﹤0.01% 8336

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Citadel Advisors's IMNM Position: Q1 2026 in Review

Citadel Advisors reduced its Immunome (IMNM) stake by 95% in Q1 2026, selling an estimated $37M and leaving 80,197 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #6364.

Citadel Advisors first reported a position in IMNM in Q3 2021 and has held it in 13 quarters since. The position peaked at $37.4M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Citadel Advisors held 80,197 shares of Immunome worth $1.75M as of Q1 2026.
  • Citadel Advisors sold 1,660,508 Immunome shares in Q1 2026, an estimated $37M.
  • Immunome made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6364 holding.
  • Citadel Advisors first reported a position in Immunome in Q3 2021 and has held it in 13 quarters since.
  • Citadel Advisors's Immunome position peaked at $37.4M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.